Concepedia

Kshitij Verma

KV

6

Publications

265

Citations

6

H-Index

2014

Active since

Affiliations

Texas Tech University Health Sciences Center(Current)

Texas Tech University

Translational Therapeutics (United States)

University of Pennsylvania

Kshitij Verma is an author at Texas Tech University Health Sciences Center specializing in drug discovery, medicine, and pharmacology.

ORCID

Top concepts

Publications per year

2014–2021

6

Publications

6

Potent and Highly Selective Aldo–Keto Reductase 1C3 (AKR1C3) Inhibitors Act as Chemotherapeutic Potentiators in Acute Myeloid Leukemia and T-Cell Acute Lymphoblastic Leukemia

Kshitij Verma, Tianzhu Zang, T.M. Penning et al. · Journal of Medicinal Chemistry · 2019 · 59 citations · Full text

Synthesis and Antineoplastic Evaluation of Mitochondrial Complex II (Succinate Dehydrogenase) Inhibitors Derived from Atpenin A5

Hezhen Wang, Bader Huwaimel, Kshitij Verma et al. · ChemMedChem · 2017 · 56 citations · Full text

AKR1C3 Inhibitor KV-37 Exhibits Antineoplastic Effects and Potentiates Enzalutamide in Combination Therapy in Prostate Adenocarcinoma Cells

Kshitij Verma, Nehal Gupta, Tianzhu Zang et al. · Molecular Cancer Therapeutics · 2018 · 55 citations

Selective AKR1C3 Inhibitors Potentiate Chemotherapeutic Activity in Multiple Acute Myeloid Leukemia (AML) Cell Lines

Kshitij Verma, Tianzhu Zang, Nehal Gupta et al. · ACS Medicinal Chemistry Letters · 2016 · 46 citations · Full text

, , +14

Screening baccharin analogs as selective inhibitors against type 5 17β-hydroxysteroid dehydrogenase (AKR1C3)

Tianzhu Zang, Kshitij Verma, Mo Chen et al. · Chemico-Biological Interactions · 2014 · 33 citations

, , +8

Rows per page

1–5 of 6